Navigation Links
CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
Date:1/15/2010

VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE CVM), a late-stage oncology company and a developer of vaccines and therapeutics for the treatment of infectious diseases, announced today the appointment of Todd S. Burkhart as Vice President of Manufacturing/Facilities and Commercial Operations for its manufacturing facility.  Mr. Burkhart has over 30 years of experience in the manufacture and process development of biologicals, medical devices and other Active Pharmaceutical Ingredients (APIs).  During his distinguished  career in the Pharmaceutical and Biopharmaceutical Industry and prior to joining CEL-SCI, Mr. Burkhart has been responsible for all aspects of GMP manufacturing and operations, including production, materials controls and facilities maintenance.  In addition he has extensive experience in the design of manufacturing facilities meeting FDA GMP requirements.  Mr. Burkhart has also been involved in the building and/or running a number of major pharmaceutical facilities at companies such as Cephalon, Human Genome Sciences and Univax Biologics.

Geert Kersten, Chief Executive Officer of CEL-SCI, said:  "We are pleased to have been able to attract to our team such an accomplished executive, with deep experience and expertise in all facets of the manufacturing process for biologics and other drugs. This hire represents another step CEL-SCI has taken in order to increase the likelihood of a successful outcome of its global pivotal Phase III study of Multikine® for the treatment of head and neck cancer."

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global pivotal Phase III clinical trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy to treat H1N1 hospitalized patients using its L.E.A.P.S. technology platform.  This investigational treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu.  This unique investigational treatment is currently being tested in a clinical study at The Johns Hopkins University Hospital.  The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

SOURCE CEL-SCI Corporation

RELATED LINKS
http://www.cel-sci.com

'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
2. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
3. CEL-SCI Corporation Releases Letter to Shareholders
4. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
5. CEL-SCI Expands H1N1 Flu Virus Work
6. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
7. CEL-SCI Posts New Corporate Presentation to Website
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Corporation Releases Letter to Shareholders
10. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Licenders is bringing their 100% all-natural lice removal service to ... at 203 13 th Street was specifically chosen to make ... "Our goal is to ease parents, stress and bring their ... children right back to class without skipping a beat. The best ... for the whole family," Licenders President Adie Horowitz states. ...
(Date:12/6/2016)... 6, 2016  "Blood Tests replace Surgical Biopsies. ... The Diagnostic, Monitoring and Screening Test opportunities ... is occurring using in vitro blood testing to ... impressive backing, has announced a single blood test ... faster than the market. New technology that definitively ...
(Date:12/6/2016)... 2016 Diabetes & Obesity Drug Development Pipeline ... disease cluster is currently dominated by therapeutics indicated for ... mellitus (T2DM), and the majority of the pipeline, in ... attributable to these indications. While products indicated for obesity ... are a large number of these products in the ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... ... December 07, 2016 , ... OC87 Recovery Diaries ... schizophrenic mother in a unique, personal perspective through animation. , That woman ... addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, lived with schizophrenia. ...
(Date:12/7/2016)... ... 2016 , ... Castle Dermatology Institute is now offering liquid facelifts with ... appearance to the face. Dr. Peyman Ghasri and Dr. Pedram Ghasri, San Fernando ... to rejuvenate and renew the facial appearance. , Sculptra is a highly effective ...
(Date:12/7/2016)... ... 07, 2016 , ... When it came time to blow out his candles on his 14th ... Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his family with ... 30th heart transplant recipient. , “He was playing at home, when we got the ...
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... offering insurance and financial planning services to families and business owners in the ... funds on behalf of the Dallas Fallen Officer Foundation. , Established in 2009 ...
Breaking Medicine News(10 mins):